Polarean Imaging plc (POLX.L)
| Previous close | 3.6500 |
| Open | 3.7390 |
| Bid | 3.6000 x 0 |
| Ask | 3.8000 x 0 |
| Day's range | 3.6000 - 3.8000 |
| 52-week range | 3.5000 - 33.0000 |
| Volume | |
| Avg. volume | 894,093 |
| Market cap | 8.002M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings date | 24 May 2024 - 28 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.43 |
Simply Wall St.Polarean Imaging (LON:POLX) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswirePolarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs
Two best-in-class lung imaging companies combine expertise for the deployment of a new xenon 129 MRI platform.Durham, NC and London, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, announced today it has partnered with VIDA Diagnostics (VIDA), a clinical imaging intelligence company providing medical imaging software solutions which manage the complexities of digital biomarkers. The compa
- GlobeNewswire
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology
The code is effective as of October 1, 2023Durham, NC, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, announces that the Centers for Medicare & Medicaid Services (CMS) has established a new reimbursement code for the Polarean XENOVIEW™ (xenon Xe 129, hyperpolarized) technology, effective October 1, 2023. The code (C9791) enables healthcare providers a path to bill for “magnetic resonance imaging with inhaled
